ArticleBMC infectious diseases2026
Clinical symptom score and risk factors for predicting post-acute sequelae of SARS-CoV-2 infection in children hospitalized with COVID-19 in Taiwan.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe clinical features and risk factors of post‑acute sequelae of SARS‑CoV‑2 infection (PASC) in children remain incomplete. This study aims to identify risk factors and evaluate the predictive utility of a clinical scoring system for PASC in pediatric patients previously hospitalized for COVID‑19.
methodsWe conducted a combined retrospective and prospective cohort study at the China Medical University Children's Hospital in Taiwan, including 143 children aged 3-18 hospitalized for the acute COVID-19 during the Omicron pandemic from April 2022 to July 2023. PASC was assessed through phone calls, online survey, and in-person follow-ups. Data encompassing demographics, clinical presentations, laboratory results, and acute-phase treatment were collected and compared between children with and without PASC. Each child was assigned total clinical scores based on the acute-phase symptoms and treatment. Multivariable logistic regression was used to identify independent predictors and evaluate the model's performance using the area under the receiver operating characteristic curve (AUC).
resultsAmong the 143 discharged children, 35.7% (n = 51) developed PASC. Children with PASC had significantly longer fever duration (3.2 vs. 2.6 days, p = 0.03), lower viral loads (higher RT-PCR Ct values: 17.1 vs. 14.2, p = 0.03) and higher rates of antiviral therapy (19.6% vs. 6.5%, p = 0.02) during the acute phase compared to those without PASC. There were no differences in age, body weight, other laboratory parameters, length of intensive care unit (ICU) stay, bacterial coinfections, and oxygen supplementation between the two groups. Notably, compared to the non-PASC group, the total clinical scores were significantly higher in the PASC group (37.9 vs. 31.5, p = 0.02). After adjusting for covariates, the multivariable prediction model achieved an AUC of 0.84.
conclusionsThis study identified a significant proportion of children developing PASC following hospitalization for acute COVID-19. Longer fever duration, low viral load (high Ct values) and antiviral therapy during the acute phase emerged as potential risk factors. Moreover, the multivariable prediction model and the clinical scoring system may support post-discharge risk stratification and help prioritize follow-up in children hospitalized for COVID-19. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.